API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AARTI DRUGS LIMITED

PART I(` in Lakhs )
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2012
Quarter Ended Financial Year Ended Consolidated
Sr. Particulars 31st Mar 2012 31st Dec 2011 31st Mar 11 31s Mar 2012 31st Mar 2011 31st Mar 2012 31st Mar 2011
No. (Audited) (Audited) (Audited) (Audited) (Audited) (Audited) (Audited)
1 Income from Operations
(a) Net Sales / Income from Operations 19,818 15,509 14,336 65,154 49,642 65,926 50,105
(Net Of Excise Duty & Sales Tax)
(b) Other Operating Income 282 3 1 291 8 610 16
Total income form operations (net) 20,100 15,512 14,337 65,444 49,650 66,536 50,120
2 Expenditure
(a).Cost of materials consumed 10,465 8,660 7,985 38,189 27,300 38,413 27,666
(b).Purchase of stock-in-trade 2,173 1,669 1,849 7,735 8,421 7,336 7,633
(c).Changes in inventories of finished goods, 1,489 353 352 (383) (1,618) (107) (1,870)
work-in-progress and stock-in-trade
(d). Employee benefits expense 718 523 476 2,335 1,787 2,485 2,147
(e).  Depreciation and amortisation expense 544 468 474 2,065 1,774 2,200 1,911
(f). Other expenses 2,679 2,591 2,057 10,053 7,490 10,594 7,831
Total expenses 18,069 14,264 13,193 59,994 45,155 60,922 45,318
3 Profit from Operations before Other Income,
finance costs and exceptional items (1-2) 2,031 1,248 1,143 5,450 4,495 5,614 4,803
4 Other Income 0 - - - -
5 Profit from ordinary activities before finance cost 2,031 1,248 1,143 5,450 4,495 5,614 4,803
and exceptional items (3+4)
6 Finance costs (interest) 650 574 409 2,082 1,348 2,267 1,492
7 Profit from ordinary activities after finance cost
but before Exceptional Items (5+6) 1,381 674 734 3,368 3,147 3,347 3,311
8 Exceptional Items - - - - - 116 -
9 Profit from Ordinary Activities before Tax (7+8) 1,381 674 734 3,368 3,147 3,231 3,311
10 Tax Expenses  (Includes) 454 193 105 1,006 900 975 961
Provision for Taxation 390 118 64 790 650 800 792
Provision for Deferred Taxation 64 74 41 216 250 176 169
11 Net profit from ordinary Activities after Tax 927 481 629 2,362 2,247 2,256 2,350
12 Extraordinary Item (net of tax expenses ) - - - - - -
Tax Provisionof Earlier Year 86 86 86 (4.88)
13 Net Profit for the period (11+12) 842 481 629 2,276 2,247 2,170 2,355
Adjustments:
(a) Adjustments on Consolidation - - (8) (9)
14 Share of profit/(loss) of associates - - - - - 8 30
15 Net profit after taxes minority interest and share of
profit /(loss) of associates (13+14+15) 842 481 629 2,276 2,247 2,169 2,376
16 Paid-up Equity Share Capital of `10/- each. 1,211 1,211 1,211 1,211 1,211 1,211 1,211
17 . Reserves & Surplus (excluding revaluation reserves) - - - 16,013 14,441 16,572 15,105
18.i Earning per share
(of ` /- each) (not annualised)
(a) Basic & Diluted 7.66 3.97 5.19 19.50 18.56 18.63 19.58




PART II

A PARTICULARS OF SHAREHOLDING
1 Public shareholding
-Number of Shares 5,379,245 5,469,811 5,569,613 5,379,245 5,569,613
-Percentage of Total Shareholding 44.43 45.17 46.00 44.43 46.00
2 Promoters & Promoter Group shareholding
a) Pledged/Encumbered
- Number of Shares Nil Nil Nil Nil Nil
-Percentage of shares(as a % of the Nil Nil Nil Nil Nil
total shareholding of promoter and promoter group)
-Percentage of shares( as a % of the Nil Nil Nil Nil Nil
total Share capital of the company)
b) Non-encumbered
- Number of Shares 6,729,305 6,638,739 6,538,937 6,729,305 6,538,937
-Percentage of shares(as a % of the total Shareholding 100 100 100 100 100
of promoter and promoter group)
-Percentage of shares( as a % of the total 55.57 54.83 54.00 55.57 54.00
Share capital of the company)
B INVESTOR COMPLAINTS Quarter ended 31st March, 2012
Pending at the begining of the quarter 0
Received during the quarter 3
Disposed of during the quarter 3
Remaining unresloved at the end of the quarter 0





STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2012  ( ` in lacs)

Particulars For the year ended Consolidated
31/03/2012 31/03/2011 31/03/2012 31/03/2011
A EQUITY AND LIABILITIES
1 Sharholder's funds
(a) Share Capital 1,211 1,211 1,211 1,211
(b) Reserves and surplus 16,013 14,441 16,572 15,105
2 Non-current liabilities
(a) Long - term borrowings 6,692 7,434 6,692 7,634
(b) Deferred tax liabilities (net) 2,446 2,230 2,447 2,271
(c) Other long - term liabilities 758 757 850 909
(d) Long - term provisions 131 - - -
Sub - total - Non - current liabilities 10,027 10,421 9,989 10,814
3 Current liabilities
(a) Short - term borrowings 18,982 14,723 20,525 16,522
(b) Trade payables 9,065 7,736 6,970 5,562
(c) Other current liabilities 2,806 2,416 2,847 2,438
(d) Short - term provisions 499 641 542 694
Sub - total -  current liabilities 31,715 25,517 31,188 25,216
TOTAL- EQUITY AND LIABILITIES 58,966 51,589 58,960 52,346
B ASSETS
1 Non-current assets
(a) Fixed assets 26,487 23,458 27,648 25,616
(b) Goodwill on consolidation - - 206 206
(c) Non - current investments 2,477 2,461 669 528
(d) Long - term loans and advances 105 863 224 961
Sub - total - Non - current assets 29,068 26,782 28,748 27,311
2 Current assets
(a) Inventories 9,277 8,316 9,746 9,183
(b) Trade receivables 17,099 12,583 16,289 12,134
(c) Cash and cash equivalents 456 359 494 527
(d) Short - term loans and advances 2,470 2,276 2,142 1,871
(e)  Other non - current assets 596 1,273 1,539 1,320
Sub - total -  current assets 29,897 24,807 30,212 25,035
TOTAL - ASSETS 58,966 51,589 58,960 52,346
Notes :
1. The above audited financial results, were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on 25th May, 2012.
2. The Board of Directors has recommended Final Dividend of Rs. 3/-per share on 1,21,08,550 Equity shares of Rs. 10/- eachfully paid-up for the Financial year 2011-12.
3. Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.
4. Amalgamation of Suyash Laboratories Ltd., wholly owned subsidiary has been approved but not effective for pending certified copies of the Bombay High Court order.
5. Figures for the previous period have been regrouped or rearranged wherever necessary.
For and on behalf of the Board
For AARTI DRUGS LIMITED
Place : Mumbai MR. HARSHIT M. SAVLA
Date: 25th May, 2012 (JT. MANAGING DIRECTOR)
 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech